A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.

Trial Details

NCT ID
NCT06022029
Phase
PHASE1
Sponsor
OncoNano Medicine, Inc.
Status
RECRUITING
Cancer Type
Melanoma
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Tamarac, Florida, United States|26.21286,-80.24977
  • Canton, Ohio, United States|40.79895,-81.37845
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Ability to understand and willingness to sign written informed consent before performance of any study procedures
  • Age ≥ 18 years
  • Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or …
  • Participants must have a minimum of one injectable and measurable lesion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →